Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00144508
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : February 2, 2009
Information provided by:
Chugai Pharmaceutical

Brief Summary:
To evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to receive either MRA or conventional DMARDs.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: MRA (Tocilizumab) Other: current treatment Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 306 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA
Study Start Date : March 2003
Actual Primary Completion Date : May 2004
Actual Study Completion Date : February 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: MRA (Tocilizumab)
8mg /kg /4week for 52 weeks
continue current treatment
Other: current treatment
continue current treatment

Primary Outcome Measures :
  1. Change in the erosion score, as determined by the modified Sharp method. [ Time Frame: week 52 ]
  2. Frequency and severity of adverse events and adverse drug reactions [ Time Frame: throughout study ]

Secondary Outcome Measures :
  1. Change in the erosion score [ Time Frame: week 28 ]
  2. Changes in the joint space narrowing score and total Sharp score [ Time Frame: week 28, 52 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Diagnosed as having RA, on the basis of the criteria stipulated by the American Conference on Rheumatism (ACR) in 1987.
  • With RA that has continued for at least 6 months but less than 5 years, with the date of first appearance being taken as the date of RA diagnosis.
  • Active RA despite at least one DMARD or immunosuppressant. Active disease is defined as having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation Committee and ESR at least 30 mm/hr and CRP not less than 2.0mg/dL.

Exclusion criteria

  • Shown to have class-IV Steinbrocker's functional activity in an evaluation carried out within 4 weeks before administration of the study drug.
  • Treated with drugs that delay joint destruction (infliximab, etanercept, leflunomide, etc.) within 3 months before administration of the study drug.
  • The oral corticosteroid dose (prednisolone equivalent of up to 10 mg/day)has not been fixed 2 weeks before administration of the study drug.
  • Subjected to any of the following within 4 weeks before administration of the study drug: (i) Change in dosage of currently administered DMARDs and/or immunosuppressive agents. (ii) Plasma exchange method. (iii) Surgical treatment (operations, etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00144508

Sponsors and Collaborators
Chugai Pharmaceutical
Study Director: Takahiro Kakehi Chugai Pharmaceutical

Responsible Party: Chugai Pharmaceutical Identifier: NCT00144508     History of Changes
Other Study ID Numbers: MRA012JP
First Posted: September 5, 2005    Key Record Dates
Last Update Posted: February 2, 2009
Last Verified: January 2009

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases